Literature DB >> 17360831

Inhibition of tumor necrosis factor-alpha through selective blockade of Pre-mRNA splicing by shikonin.

Shao-Chih Chiu1, Ning-Sun Yang.   

Abstract

We previously developed a gene-gun-based in vivo screening system and identified shikonin as a potent suppressor of tumor necrosis factor-alpha (TNF-alpha) gene expression. Here, we show that shikonin selectively inhibits the expression of TNF-alpha at the RNA splicing level. Treatment of lipopolysaccharide-stimulated human primary monocytes and THP-1 cells with shikonin resulted in normal transcriptional induction of TNF-alpha, but unspliced pre-mRNA accumulated at the expense of functional mRNA. This effect occurred with noncytotoxic doses of shikonin and was highly specific, because mRNA production of neither a housekeeping gene nor another inflammatory cytokine gene, interleukin-8 (IL-8), was affected. Moreover, cotreatment with lipopolysaccharide (LPS) and shikonin increased the endpoint protein production of IL-8, accompanied by suppressed activation of the double-stranded RNA-activated protein kinase (PKR) pathway. Because PKR inactivation has been shown to down-regulate the splicing process of TNF-alpha RNA and interfere with translation, our findings suggest that shikonin may achieve differential modulation of cytokine protein expression through inactivation of the PKR pathway and reveal that regulation of TNF-alpha pre-mRNA splicing may constitute a promising target for future anti-inflammatory application.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17360831     DOI: 10.1124/mol.106.032821

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  18 in total

1.  Shikonin reduces oedema induced by phorbol ester by interfering with IkappaBalpha degradation thus inhibiting translocation of NF-kappaB to the nucleus.

Authors:  I Andújar; M C Recio; T Bacelli; R M Giner; J L Ríos
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

2.  Shikonin inhibits TNF-α production through suppressing PKC-NF-κB-dependent decrease of IL-10 in rheumatoid arthritis-like cell model.

Authors:  Wen-Xiao Sun; Yan Liu; Wei Zhou; He-Wei Li; Jian Yang; Zhen-Bing Chen
Journal:  J Nat Med       Date:  2016-12-09       Impact factor: 2.343

3.  Differential functional genomic effects of anti-inflammatory phytocompounds on immune signaling.

Authors:  Shao-Chih Chiu; Shan-Wen Tsao; Pei-Ing Hwang; Staniforth Vanisree; Yi-An Chen; Ning-Sun Yang
Journal:  BMC Genomics       Date:  2010-09-24       Impact factor: 3.969

4.  Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo.

Authors:  Huanjie Yang; Ping Zhou; Hongbiao Huang; Di Chen; Ningfang Ma; Qiuzhi Cindy Cui; Shouxing Shen; Weihua Dong; Xiaoyan Zhang; Wen Lian; Xuejun Wang; Q Ping Dou; Jinbao Liu
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

5.  Shikonin enhances efficacy of a gene-based cancer vaccine via induction of RANTES.

Authors:  Hui-Ming Chen; Pi-Hsueh Wang; Kandan Aravindaram; Yun-Hsiang Chen; Hsiu-Hui Yu; Wen-Chin Yang; Ning-Sun Yang
Journal:  J Biomed Sci       Date:  2012-04-12       Impact factor: 8.410

6.  Topical application of marine briarane-type diterpenes effectively inhibits 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and dermatitis in murine skin.

Authors:  Wen-Chi Wei; Sheng-Yen Lin; Yi-Jyun Chen; Chih-Chun Wen; Chiung-Yao Huang; Arulselvan Palanisamy; Ning-Sun Yang; Jyh-Horng Sheu
Journal:  J Biomed Sci       Date:  2011-12-21       Impact factor: 8.410

7.  The Phytochemical Shikonin Stimulates Epithelial-Mesenchymal Transition (EMT) in Skin Wound Healing.

Authors:  Shu-Yi Yin; An-Ping Peng; Li-Ting Huang; Ya-Ting Wang; Chun-Wen Lan; Ning-Sun Yang
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-03       Impact factor: 2.629

8.  Shikonin Suppresses Human T Lymphocyte Activation through Inhibition of IKK β Activity and JNK Phosphorylation.

Authors:  Ting Li; Fenggen Yan; Rui Wang; Hua Zhou; Liang Liu
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-16       Impact factor: 2.629

9.  Shikonin directly targets mitochondria and causes mitochondrial dysfunction in cancer cells.

Authors:  Benjamin Wiench; Tolga Eichhorn; Malte Paulsen; Thomas Efferth
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-15       Impact factor: 2.629

10.  Preparation, cellular uptake and angiogenic suppression of shikonin-containing liposomes in vitro and in vivo.

Authors:  Hongmei Xia; Chengyi Tang; Heng Gui; Xiaoming Wang; Jinliang Qi; Xiuqiang Wang; Yonghua Yang
Journal:  Biosci Rep       Date:  2013-02-01       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.